Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Center for International Blood and Marrow Transplant Research
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Allogene Therapeutics
BeOne Medicines
Dartmouth-Hitchcock Medical Center
Seattle Children's Hospital
M.D. Anderson Cancer Center
GeoVax, Inc.
Center for International Blood and Marrow Transplant Research
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Seattle Children's Hospital
Fate Therapeutics
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Children's Hospital of Philadelphia
National Cancer Institute (NCI)
Children's Oncology Group
University College, London
University of Alabama at Birmingham
University Hospital, Angers
National Cancer Institute (NCI)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Weill Medical College of Cornell University
Rigshospitalet, Denmark
Montreal Heart Institute
Memorial Sloan Kettering Cancer Center
Rigshospitalet, Denmark
City of Hope Medical Center
Tempus AI
City of Hope Medical Center
Stanford University
Ono Pharmaceutical Co. Ltd
UNC Lineberger Comprehensive Cancer Center